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Abstract 
This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally‑tolerated doses 
(MTD), dose‑limiting toxicities, response‑to‑therapy, and explored the role of novel response biomarkers. MA.22 
accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was 6 cycles of 3‑weekly (Schedule A; N = 47) 
or 8 cycles of 2‑weekly (Schedule B; N = 46) epirubicin/docetaxel chemotherapy in sequential phase I/II studies, 
with growth factor support. In phase I of each schedule, MTDs were based on DLT. In phase II, clinical responses (CR/
PR) and pathologic complete responses (pCR) were assessed. Tumor biopsy cores were obtained pre‑, mid‑, and 
post‑treatment: 3 for pathologic assessment; 3 for microarray studies. DLT for Schedule A was febrile neutropenia at 
105 mg/m2 epirubicin and 75 mg/m2 docetaxel; for schedule B, it was fatigue at 75 mg/m2 for both agents. Phase II 
doses were 90 mg/m2 epirubicin/75 mg/m2 docetaxel for Schedule A and 60 mg/m2 (both agents) for Schedule B. 
Schedule A CR/PR and pCR rates were 90 and 10 %, with large reductions in tumor RNA content and integrity follow‑
ing treatment; Schedule B results were 93 and 0 %, with smaller reductions in RNA quality. Pre‑treatment expression 
of several genes was associated with clinical response, including those within a likely amplicon at 17q12 (ERBB2, 
TCAP, GSDMB, and PNMT). The combination regimens had acceptable toxicity, good clinical response, induction of 
changes in tumor RNA content and integrity. Pre‑treatment expression of particular genes was associated with clinical 
responses, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.
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Background
LABC is traditionally defined as stage IIB (T3N0) and 
Stage IIIA/B/C from the TMN classification (Chia et al. 
2008; Hortobagyi et al. 1995). LABC represents 10–15 % 
of breast cancer cases, with 5-year survival of 30–42  % 
of patients (Canadian Cancer Society et  al. 2012), a 
significant portion of whom will have metastatic dis-
ease. However, a small subset of women who receive 
neoadjuvant chemotherapy and achieve a pathologic 
complete response (pCR), defined as no microscopic 
residual invasive disease following treatment, have a sig-
nificantly improved 5-year disease-free survival (DFS) 
rate of about 87  %, and 5-year overall survival (OS) 
rates near 90  % (Kuerer et  al. 1999). pCR rates have 
thus become an accepted surrogate measure for favora-
ble long-term outcomes after neoadjuvant chemother-
apy (Mieog et  al. 2007; Sinclair and Swain 2010; Specht 
and Gralow 2009). While pCR appears to be associated 
with ultimate DFS and OS outcomes, patients with cer-
tain tumor subtypes have substantially lower pCR rates, 
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but can still have favorable outcomes (Carey et al. 2007; 
Esserman et al. 2012; Rouzier et al. 2005). Early biomark-
ers, preferably before systemic therapy, would signifi-
cantly enhance patient care (Carey et al. 2007; Esserman 
et al. 2012; Carey and Winer 2014; Cortazar et al. 2014; 
Houssami et al. 2012).
A number of commonly used anthracycline and taxane 
containing regimens have been studied in combination 
(TAC) or in sequence [dd(AC-P), AC-weekly P, FEC-
D, AC-D] (Aigner et  al. 2011; Gandhi et  al. 2015; Raza 
et al. 2009). (Where T or D = docetaxel; P = paclitaxel; 
A = doxorubicin; C =  cyclophosphamide; F = 5 fluoro-
uracil; dd  =  dose-dense). However, optimal doses and 
schedules for anthracycline/taxane combination regimens 
have not been established for epirubicin and docetaxel. 
We examined the efficacies and toxicities associated with 
epirubicin/docetaxel combination chemotherapy at vari-
ous doses and schedules for women with LABC. We also 
conducted exploratory tumor genome profiling studies 
for prospective biomarkers of response to the regimens.
Patients and methods
Study design
The NCIC Clinical Trials Group MA.22 is a non-ran-
domized phase I/II clinical trial (ClinicalTrials.gov 
identifier NCT00066443) to determine optimal dosing 
regimens for docetaxel/epirubicin combination chemo-
therapy in women with locally advanced or inflammatory 
breast cancer. The protocol was approved by Health Can-
ada and local Ethics Review Boards; patients provided 
written, informed consent.
Escalating doses of epirubicin and docetaxel were 
administered to patients in either a standard q3 weekly 
(Schedule A) or dose dense q2 weekly (Schedule B) regi-
men. Doses for Schedule A were 75  mg/m2 IV of doc-
etaxel and 75, 90, 105, or 120  mg/m2 IV of epirubicin 
(with pegfilgrastim 6  mg primary prophylaxis sc per 
cycle on day 2). Doses for both docetaxel and epiru-
bicin in Schedule B were 50, 60, and 70 mg/m2 IV (with 
pegfilgrastim support). For each schedule, phase I was 
dose finding for phase II. Cohorts of three patients were 
recruited at each dose level with three additional patients 
recruited if a dose limiting toxicity (DLT) was observed. 
If two or more DLTs were noted, the dose level was 
declared as the Maximum Tolerated Dose (MTD) and 
the phase II component of the trial was opened at the 
dose level below the MTD. DLTs may have been hema-
tological, non-hematological, or related to the inability 
to deliver therapy and are defined in Table  1. None of 
the patients received trastuzumab initially and HER2+ 
patients were not enrolled on study, once trastuzumab 
funding became available. The microarray data have been 
uploaded to the Gene Expression Omnibus (GEO) portal 




Eligible patients had histologically confirmed invasive 
adenocarcinoma of the breast, which met the follow-
ing criteria: T3N0, any N2 or N3, or inflammatory car-
cinoma. Patients had no clinical or radiological evidence 
of distant disease and no previous treatment for breast 
cancer. Age was >16 years, with ECOG status of 0–2, and 
adequate bone marrow, hepatic and renal function. Left 
ventricular ejection fraction must have been within the 
institutional norm.
Study oversight
Data were collected, managed, and analyzed by the NCIC 
CTG. The NCIC CTG Data Safety Monitoring Com-
mittee reviewed study conduct, safety, and efficacy on a 
6-monthly basis. The trial committee made the decision 
to publish the results. Manuscript writing was under-
taken entirely by the first author, coauthors, and staff at 
the NCIC CTG central office, who vouch for the fidelity 
of the study and the data.
Study endpoints
The primary objective of the phase I portion of each 
schedule was to identify DLTs, the MTD, and the dose for 
the q3 weekly and q2 weekly regimens. Phase I secondary 
objectives were to conduct microarray and immunohis-
tochemical assessments of biomarker sensitivity/resist-
ance to epirubicin and docetaxel.
Table 1 Toxicities associated with  docetaxel/epirubicin 
chemotherapy for MA.22 patients in Schedules A or B
a Toxicities were determined by using NCI Common Toxicity CriteriaV2.0
Toxicitiesa Schedule A (N = 47) Schedule B (N = 46)
Febrile neutropenia 6 (DLT Phase I) 0
Fever 1 0
Infections without  
neutropenia
2 1
Fatigue 1 7 (DLT Phase I)
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The primary objective of phase II for both schedules 
was to evaluate clinical response rates at selected dose 
levels. Clinical response was defined as complete clinical 
response (CR; absence of disease by palpation post-treat-
ment) or partial response (PR; patients with caliper meas-
urements exhibiting a decrease in tumor volume ≥50 %). 
Patients with tumor volume decreases <50 % were con-
sidered to have stable disease (SD). If tumors increased in 
size, then patients had progressive disease (PD).
In phase II, secondary objectives were to examine pCR 
rates (pathologic absence of tumor in the breast and 
axillary lymph nodes at primary surgery), duration of 
response (time from CR or PR until progression), toxici-
ties by NCI Common Toxicity Criteria V2.0, biomarker 
assessments of response to therapy, and time to dis-
tant metastasis (defined as time from registration to the 
first evidence of recurrent disease) and survival (time 
to death). The pCR rate was too low for pCR to be used 
as an endpoint for biomarker assessments so clinical 
response was used.
Tumor core biopsies and isolation of tumor RNA
Six image-guided core biopsies of tumors were obtained 
pre-treatment; mid-treatment, at 3 (q3 weekly) or 4 (q2 
weekly) cycles of chemotherapy; and post-treatment at 
6 (q3 weekly) or 8 (q2 weekly) cycles (Additional file  1: 
Appendix S1). Three biopsies at each time point were 
stored in formalin for histological and immunohisto-
chemical studies, while three were flash frozen and stored 
in liquid nitrogen (−190  °C). For RNA isolation, the 
methods were as previously described (Parissenti et  al. 
2010). Frozen biopsies were homogenized in RLT buffer 
and the RNA isolated using a Qiagen RNeasy™ RNA iso-
lation kit (Qiagen Inc., Toronto, ON, Additional file  1: 
Appendix S1). Samples (in 35  μl of RNase-free water) 
were then stored at −80 °C. RNA quality was assessed by 
applying 1 μl of the preparation onto Caliper™ RNA nan-
ochips (Caliper Technologies, Hopkinton, MA) and using 
capillary electrophoresis on an Agilent 2100 Bioanalyzer 
to resolve component RNAs. The Bioanalyzer software 
generated an RNA integrity number (RIN) between 1 and 
10, where 10 represents highly intact RNA and 1 repre-
sents highly degraded RNA.
Microarray profiling of gene expression
High RNA quality (RIN ≥5) was necessary for micro-
array assessment, and treatment frequently reduced 
mid-treatment RIN to levels <5. A surrogate endpoint 
of mid-treatment RIN (<5, ≥5) was utilized to exam-
ine baseline genes associated with RIN level, in addition 
to the examinations of genes associated with clinical 
response. High throughput gene expression studies using 
Agilent 4 ×  44  k human genome arrays (27,958 human 
Entrez gene probes representing almost the entire pro-
tein-coding genome) were conducted on RNA prepara-
tions from pre- and mid-treatment tumor samples with 
RIN ≥5.0 The protocol used is described in Additional 
file 1: Appendix S1.
Histological and Immunohistochemical Characterization 
of Tumors
The histological features as well as extent of tumor in 
the core biopsies were evaluated on H&E sections. Pre-
treatment, the expression of cell surface receptors were 
assessed by immunohistochemical microscopy: estrogen 
receptor (ER; clone 6G11, Novocastra), progesterone 
receptor (PR; clone 16, Novocastra), Her2/Neu receptor 
(HER2; TAB 250, ZYMED), and topo2 (clone SWT3D1, 
DAKO) (Parissenti et al. 2010).
Statistical analysis
Reporting is by Schedule for all analyses. All patients 
who received at least one dose of study treatment were 
included in the safety reports, subdivided by schedule 
and phase. Phase II DFS and OS were described with 
Kaplan–Meier plots. Biomarkers were assessed for all 
patients; ER, PR, Her2, and Topo2 immunohistochemical 
assessments were used to characterize tumors.
Full genome profiling was conducted using Agilent 
microarrays, where RNA was of sufficient quantity 
and quality (RIN ≥5) for profiling. Some RNAs were 
not available for Agilent gene profiling due to their 
use on prior microarrays of inferior quality, such that 
all patient tumors could not be profiled. The quality of 
the prior microarray data was insufficient to combine 
with the Agilent data. Exact Fisher tests (categorical 
factors) and Wilcoxon signed-rank tests (continuous 
factors) were used to compare the patient and tumor 
characteristics for patients with, or without, Agilent 
assessments. BRB array tools (version 4.2.1) were used 
to examine baseline gene expressions for exploratory 
identification of genes associated with response to epi-
rubicin/docetaxel chemotherapy (class prediction), 
where response was defined in separate assessments 
as clinical response, and as RIN (<5, ≥5) at mid-
treatment. We examined gene expression changes for 
patients who had both pre- and mid-treatment arrays 
with RIN ≥5.0 (class comparisons), to examine the 
association of gene expression changes with hormone 
receptor status (ER/PR), HER2, Topo2, and treatment 
dose (ANOVA to examine fixed effects; paired t-tests to 
examine differentially expressed genes). P values <0.001 
were considered significant; we considered a false dis-
covery rate (FDR) of <0.1.
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Results
MA.22 accrued 93 patients from February 25, 2003 to 
June 9, 2009; 47 to Schedule A, 46 had tumor blocks and 
46 to Schedule B, all of whom had tumor blocks (CON-
SORT diagram, Fig.  1 outlines enrollment by schedule). 
Patient and tumor characteristics data are presented by 
schedule in Table 2. Five Schedule A and 11 Schedule B 
patients did not have Agilent assessments; PR levels were 
higher in those not assessed (p = 0.04; 0.01, respectively).
The phase I MTD for the three weekly regimen (Sched-
ule A) was 120  mg/m2 epirubicin and 75  mg/m2 doc-
etaxel, with the phase II portion conducted at 105 and 
75  mg/m2, respectively. The clinical response rate for 
Schedule A was 28/31 (90.3  %), with median duration 
of response of 2  years (range 0.1–5.6) and 3/31 (9.7  %) 
pCR. For the dose dense (2 weekly) regimen (Schedule 
B), the MTD was 75 mg/m2 for both agents. In the phase 
2 portion, patients received 60 mg/m2 of both drugs; the 
clinical response rate was 28/30 (93.3  %) with median 
duration of response of 0.2 years (range 0.1–3.9) and no 
pCR.
Table 1 outlines grade 3 or 4 toxicities for all patients. 
The DLT for Schedule A was febrile neutropenia, while 
for Schedule B, DLT was fatigue. None of the toxicities 
were unexpected for the combination of epirubicin and 
docetaxel.
Disease‑free survival
Recruitment for Schedule B began after that for Schedule 
A: median follow-up for Schedule A was 7.3 years (95 % 
CI 6.6–7.6), with 50 months DFS 59 % (95 % CI 39–74 %; 
Additional file 1: Figure S1A); Schedule B median follow-
up was 3.6 years (95 % CI 3.5–4.0), with 50 months DFS 
60  % (95  % CI 31–80  %; Additional file  1: Figure  S1B).
Time to distant mestatases and overall survival will not 
be reported here.
RNA integrity (RIN) and pCR
Tumor RNA integrity decreased significantly (p < 0.001) 
following chemotherapy. For Schedule A, phase II 
patients from a pre-treatment mean of 5.4 (95  % CI 
5.1–5.7) to mid-treatment 1.9 (95  % CI 1.6–2.2) and 
post-treatment 1.9 (95  % CI 1.5–2.3) (Additional file  1: 
Table S1). Mean tumor RIN values for Phase II patients in 
Schedule B also significantly decreased (p < 0.0001) from 
pretreatment 5.8 (95 % CI 5.5–6.1) to mid-treatment 4.3 
(95 % CI 4.0–4.6) and post-treatment 2.9 (95 % CI 2.6–
3.2). The effect of treatment on tumor RNA integrity is 
evident in scatter plots of maximum tumor RIN versus 
tumor RNA concentration for Schedule A and B patients 
prior to and during treatment (Additional file  1: Figure 
S2), where treatment resulted in a clustering of patient 
tumor samples to regions of low RIN and low RNA 
concentration values. This occurred for both patients 
that achieved a pCR and those that did not.
Figure  2 depicts maximum tumor RIN by schedule, 
dose level, and treatment period for all patients accrued 
to that schedule. Schedule A patients (Fig.  2a) did not 
have significantly different pre-treatment RIN, mid- and 
post-treatment RIN (p  =  0.40; 0.24; 0.17, respectively). 
Schedule B patients (Fig. 2b) had different RIN pre-treat-
ment (p = 0.06) and post-treatment (p = 0.03), although 
not at mid-treatment (p  =  0.29). The composite of all 
patients accrued to two MA.22 schedules is shown in 
Fig. 2c and summarized in Additional file 1: Table S1.
Analysis of gene expression in tumor core biopsies
In all Schedule A patients for whom tumor RNA qual-
ity pre-treatment was sufficient in quantity and quality 
for DNA microarray analysis, 10 had a complete clinical 
response (CR), 30 had a partial response (PR), and 1 had 
stable disease (SD). No Schedule A patients exhibited 
disease progression (PD). Eleven genes had significantly 
altered expression in the tumors of patients who exhib-
ited a CR in Schedule A compared to patients that had a 
PR, SD, or PD or were differentially expressed between 
27 patients with tumor RIN <5 and 14 patients with 
tumor RIN ≥5 (Table 3 Schedule A for clinical response 
(Ammann et  al. 2013; Benusiglio et  al. 2006; Boucquey 
et al. 2006; Coon et al. 2002; Katoh 2004; Marshall et al. 
1979; Nicholas et  al. 2002; Pritchard et  al. 2006; Qiu 
et al. 2014; Rauch et al. 2006; Saeki et al. 2009; Staaf et al. 
2010); Additional file  1: Table  S2 for RIN (Wang et  al. 
2011; Yosten et al. 2012; Zudaire et al. 2008); and Fig. 3a). 
In Schedule B, the pre-treatment expression of 9 tumor 
genes has associations with clinical response (3 CRs, 27 
PR, 4SD, 1PD) or were differentially expressed between 
18 patients with tumor RIN <5 and 17 patients with 
tumor RIN >5 (Table 3 Schedule B for clinical response 
(Biaoxue et  al. 2012; Cagnoni and Tamagnone 2014; 
Campbell et al. 2013; Malik et al. 2014; Sakwe et al. 2011; 
Yuan et  al. 2006; Zhang et  al. 2013); Additional file  1: 
Table S2 for RIN (Araki and Milbrandt 2000; Feng et al. 
2006; Inuzuka et  al. 2005; Liedtke et  al. 2007; Salzman 
et  al. 2011); and Fig.  3b). The numbers of genes associ-
ated with change in matched pre- and mid-treatment 
samples and with immunohistochemical biomarkers or 
dose greatly exceeded the sample size so are not reported 
here.
Discussion
A clinical CR or PR after neoadjuvant chemotherapy 
are relatively common in LABC patients; however, 
despite these responses there is still frequently residual 
disease found within the breast or axilla post-treat-
ment (Guarneri et  al. 2006). While pCR rates have 
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been associated with a survival benefit from treatment, 
such a benefit has not been shown for patients with 
LABC (Mieog et  al. 2007; Sinclair and Swain 2010; 
Specht and Gralow 2009). Indeed, pCR rates remain 
low in patients with LABC, especially those patients 
who have ER  +/Her2- disease, i.e. the majority of 
breast cancer patients (Kuerer et  al. 1999; Guarneri 
et  al. 2006; Liu et  al. 2010). In this study, while more 
than 90 % of patients had either a CR or PR, less than 
10 % of patients exhibited a pCR. It is likely that pCR 
underestimates the effects of chemotherapy in certain 
patients.






































Fig. 1 CONSORT diagram
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In this study, we provide hypothesis generating evi-
dence for additional biomarkers that may help predict 
a long-term favorable response to chemotherapy or 
monitor response to chemotherapy in real time. Chem-
otherapy treatment was found to be associated with a 
reduction in tumor RNA content and RNA integrity.
Her2-overexpressing breast tumors are known to be 
highly clinically responsive to chemotherapy (Guarneri 
et al. 2006; von Minckwitz et al. 2012). Interestingly, for all 
patients undergoing microarray analysis in our study, in 
the absence of Herceptin, HER2/ERBB2 transcripts were 
>fivefold higher in patients that had a CR after chemo-
therapy compared to patients with a PR, SD, or PD. The 
expression of 3 additional genes within 17q12 (GSDMB, 
PNMT, TCAP) had 3.7- to 13.3-fold higher expression in 
CR patients (Table 3 Schedule A). This higher expression 
may be related to an amplification of 17q12 in respond-
ing tumors. Amplification of 17q12–q21 is common in 
ERBB2 overexpressing breast cancers, particularly in a 
280  kb region that includes the 3 additional genes iden-
tified above (Kauraniemi and Kallioniemi 2006). Thus, 
in addition to HER2/ERBB2, our data suggests that 
the expression of all four genes is associated with a CR 
post-chemotherapy. As shown in the heat map depiction 
of patient gene expression data, some patients with CRs 
did not exhibit HER2 overexpression, but exhibited over-
expression of other genes associated with a CR, including 
SINGLEC11, ONECUT2, and/or BTN2A2 (Fig. 3a).
The above overexpressed genes within 17q12 reside on 
chromosome 17 in the following order: TCAP, PNMT, 
ERBB2, and GSDMB. In this study, their tumor expres-
sion was 3.7-, 13.3-, 5.6-, and 4.0-fold higher in clinical 
responders, respectively. This suggests that the ampli-
fication may be centered on PNMT rather than ERBB2, 
or the amplification has a greater effect on PNMT tran-
scription. The PNMT amplification or overexpression 
could be a more sensitive or reliable biomarker of clini-
cally chemoresponsive breast cancer than Her2 overex-
pression. Moreover, the additional genes identified in this 
study may improve our ability to predict clinical response 
to chemotherapy.
The ability of these additional genes to predict or affect 
clinical response to chemotherapy may be related to their 
roles in cells. Gasdermin-B (the GSDMB gene product) has 
been shown to promote tumor formation, invasion, and 
metastasis in mouse xenograft models and the expression 
Table 2 Patient and tumour characteristics and response by whether patient’s tumour assessed by agilent microarray
1 P value is based on Fisher’s exact test for categorical factors and Wilcoxon signed-rank test for continuous




Yes (N = 41) No (N = 5) Total (N = 46) P value1 Yes (N = 35) No (N = 11) Total (N = 46) P value1
Clinical N stage N1 17 1 18 8 2 10
N2 15 3 18 24 5 29
N3 3 0 3 2 3 5
NX 6 1 7 1 0 1
N0 0 0 0 0.6983 0 1 1 0.1074
Clinical T stage T2 2 0 2 1 0 1
T3 13 1 14 18 5 23
T4 26 4 30 16 4 20
T1 0 0 0 0 1 1
TX 0 0 0 1.0000 0 1 1 0.2185
Age Median 48.5 47.8 41.8 45.4
Range (27.4, 72.3) (44.1, 72.2) 0.3061 (28.2, 65.2) (27.5, 60.1) 0.7088
ER Median 40 100 0 100
Range (0, 100) (0, 100) 0.3909 (0, 100) (0, 100) 0.1919
PR Median 0 60 0 100
Range (0, 100) (0, 100) 0.04134 (0, 100) (0, 100) 0.01362
Her2 Median 0 0 0 0
Range (0, 100) (0, 0) 0.06909 (0, 100) (0, 0) 0.5997
Topo2 Median 70 90 80 100
Range (0, 100) (0, 100) 0.4537 (0, 100) (1, 90) 0.1411
% tumour extent Median 100 90 85 80
Range (40, 100) (60, 100) 0.2862 (0, 100) (1, 100) 0.9887
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Schedule B:  baseline p=0.06,  mid-treatment p=0.29,  post-treatment p=0.03



















Fig. 2 a Schedule A maximum RIN by dose level and treatment time. b Schedule B maximum RIN by dose level and treatment time. c Schedule A 
and B maximum RIN by dose level and treatment time
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of gasdermin-related genes was correlated with reduced 
survival in breast cancer patients (Hergueta-Redondo et al. 
2014). Thus, the poor prognosis associated with HER2 
overexpression in breast cancer (and its relationship to 
enhanced clinical response to chemotherapy) may also be 
related to the overexpression of Gasermin B. Titin-Cap 
(the TCAP gene product) blocks the secretion of myosta-
tin, a transforming growth factor β (TGF-β) family member 
that negatively regulates cell growth (Nicholas et al. 2002). 
Since myostatin promotes apoptosis in breast tumor cells 
(Liu et  al. 2013), the overexpression of Titin-Cap would 
be expected to strongly promote breast tumor prolifera-
tion. This would render cells more sensitive to killing by 
chemotherapy agents that target rapidly dividing tumors. 
It is unclear how PNMT (phenylethanolamine N-meth-
yltransferase), which catalyzes the conversion of norepi-
nephrine to epinephrine as the last step in epinephrine 
biosynthesis, might play a role in chemotherapy response. 
Two other genes whose expression pre-treatment was sig-
nificantly elevated in chemoresponsive tumors (BTN2A2 
and ONECUT2) would be expected to improve clinical 
response to chemotherapy, since the enhanced expres-
sion of the former gene inhibits AKT-dependent survival 
pathways and is associated with improved patient progno-
sis (Ammann et al. 2013), while the latter gene is a known 
tumor suppressor gene (Rauch et al. 2006).
Table 3 Genes whose expression pretreatment is associated with clinical response to chemotherapy as measured by cali-
pers
Gene Fold change CR/
(PR + SD + PD)
Fold change  
CR/PR
Role and references Chromosomal 
location
Schedule A
 PGM2 N.S. −2.0 Phosphoglucomutase‑2; deletion mutation in cervical cancer 
(Marshall et al. 1979)
4p14
 GSDMB +4.0 +3.8 Gasdermin B; overexpressed in gastric and esophageal cancers; 
expressed in proliferating cells, but not differentiated cells; site 
of recombination hotspot around ERBB2 (Katoh 2004; Saeki et al. 
2009)
17q12
 ERBB2 +5.6 +5.2 ERBB2; Highly correlated to clinical response in breast cancer (Coon 
et al. 2002; Pritchard et al. 2006)
17q12
 FAM114A1 −2.0 −2.0 Also called NOXP20; protein overexpressed in the nervous system 
(Boucquey et al. 2006)
4p14
 PNMT +13.25 Phenylethanolamine N‑methyltransferase; associated with ERBB2 
amplification, catalyzes synthesis of epinephrine to norepineph‑
rine (Staaf et al. 2010)
17q12
 BTN2A2 +2.2 Butyrophilin; Inhibits AKT pathway; expression in epithelial and ovar‑
ian cancer associated with higher infiltrating T cells; associated 
with better prognosis (Ammann et al. 2013)
6p22
 TCAP +3.7 Titin‑Cap protein; associated with the ERBB2 amplicon in breast 
cancer; associated with ERBB2 genetic polymorphisms associ‑
ated with gastric cancer; associated with growth factor myostatin 
(Benusiglio et al. 2006; Nicholas et al. 2002; Qiu et al. 2014)
17q12
 ONECUT2 +4.9 Tumor suppressor gene repressed in lung cancer; promotes growth 







Fold change  
PR/SD
Role and references Chromosomal 
location
Schedule B
 PSTK +2.7 Phosphoseryl tRNA Sec Kinase; involved in selenocysteine 
biosynthesis; important for ribosomal protein synthesis 
(Yuan et al. 2006)
10q
 ANXA6 −1.8 Annexin A6; activates NF‑ĸB survival pathway, contributes 
to invasiveness in breast cancer cells; correlates with poor 
survival/mets in lung cancer (Biaoxue et al. 2012; Campbell 
et al. 2013; Sakwe et al. 2011)
5q32
 LINGO1 −3.1 LINGO 1 protein; promotes apoptosis (Zhang et al. 2013) 15q24
 SEMA4D +33 Semaphorin 4A; binds to Plexin B1, which physically associ‑
ates with and activates ERBB2 (Cagnoni and Tamagnone 
2014; Malik et al. 2014)
1q22
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Fig. 3 a Schedule A heat map of patient gene expression data. b Schedule B heat map of patient gene expression data
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This study has limitations due to its small sample size; 
however, evidence is provided for two schedules of epi-
rubicin and docetaxel therapy with hypothesis generating 
evidence for the potential value of the quality assurance 
measure RIN. Reductions of RIN that prevent microar-
ray assessments after chemotherapy may in fact be a 
surrogate for clinical responsiveness to therapy. While 
most (≥90 %) of MA.22 patients had a clinical response, 
the proportion of patients with mid-treatment RIN that 
was too low for microarray assessment was much lower. 
However, neither clinical response nor RIN reduction 
was reflective of the low pCR rates seen here, which is the 
context in which identified genes may be useful for explo-
ration elsewhere.
Conclusion
In summary, the MA.22 clinical trial revealed that epi-
rubicin/docetaxel combination chemotherapy can be 
delivered in LABC patients with acceptable toxicity. This 
regimen can, in some patients, induce strong reductions 
in tumor RNA integrity that are associated with post-
treatment pCRs. Elevated expression of specific genes 
within 17q12 near the HER2/ERBB2 locus (and other 
genes) were found to be associated with a complete 
clinical response to epirubicin/docetaxel chemotherapy. 
These genes could represent new targets for drug devel-
opment that could improve clinical response to future 
regimens.
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